Abstract:Abstract The current drug development is a very expensive and prolonged process with high attrition rate, especially in the oncology drug development. New tools with dynamic and quantitative modeling and experimental support are needed to accelerate the drug discovery process and increase productivity. The process begins with building a quantitative model of biological regulatory system based on the extensive data-mining from literature and experiments. By incorporating the preclinical PK/PD data relevant to the target system, a new computational model under drug perturbation can be built. Through iterative process of hypotheses generating and experimental testing, such models can be fine-tuned. Consequences of particular perturbations, such as optimal dosage and treatment schedules, optimal drug target, and combination therapy can be simulated in time course using such models. A better understanding of the biological system will be gained and better therapeutic interventions suggestions can be provided. In this study, we use NF-κB pathway as an example study considering NF-κB pathway has become a focal point for intense drug discovery and development efforts. Dynamic drug perturbation is incorporated in the model stem from Hoffmann et al. (science 2002 Nov 8;298) through hybrid system theory to link dose – concentration relationships (PK) and concentration – effect relationships (PD). This approach facilitates the description and prediction of the time course of drug effects resulting from a certain dose regimen. Extensive simulations of the proposed model are performed in MATLAB/SIMULINK. An important observation is that there exists a “sweet spot” for certain dosage and frequency arrangements given the totaled delivered drug. The perturbation effect for different targets is simulated and compared in this model. However, the specificity of some drugs to inhibit several of these components of the NF-κB pathway is one of the concerns. For example, if we block the degradation pathway of IκB by using proteasome inhibitor (such as Bortezomib) to inhibit ubiquitination of IκB by the 26S protesome. The side effects are unacceptable when the drug is effective. Hence, we design combination therapy to induce a acceptable combined effect and using lower doses for each drugs. We observe that some combinations of the drugs with non-overlapping toxicities might provide enormous benefit. While such dynamical modeling approaches are still in their infancy, advancing techniques of the quantitative single live cell measurement of the protein processes will provide us more accurate parameters and help us to test and confirm some observations. This will allow a better understanding of the kinetics and function of mechanisms within regulatory networks. The authors believe that appropriate models can help establishing a mechanistic understanding of the disease and of drug action instead of the traditional “black-box” approach in drug discovery. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4921. doi:10.1158/1538-7445.AM2011-4921

Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models

Quantitative Modeling of Dose–response and Drug Combination Based on Pathway Network

Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer.

Elucidation of differential response networks from toxicogenomics data

Mechanistic Insights into Metabolic Disturbance During Type-2 Diabetes and Obesity Using Qualitative Networks.

Network Reconstruction for Trans Acting Genetic Loci Using Multi-Omics Data and Prior Information

Systems Perturbation Analysis of a Large Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics

Social networks help to infer causality in the tumor microenvironment

Abstract 4921: Dynamic and quantitative modeling of drug effect

Assessing network-based methods in the context of system toxicology

Perturbation Biology: Inferring Signaling Networks in Cellular Systems

Qualitative and Quantitative Concentration-Response Modelling of Gene Co-expression Networks to Unlock Hepatotoxic Mechanisms for Next Generation Chemical Safety Assessment

An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer.

In silico Genetic Network Models for *Pre-clinical Drug Prioritization

Identification of Phenotypic Networks Based on Whole Transcriptome by Comparative Network Decomposition

Reconstruction of cellular signal transduction networks using perturbation assays and linear programming

Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone

Allele-specific behavior of molecular networks: understanding small-molecule drug response in yeast.

From classical mendelian randomization to causal networks for systematic integration of multi-omics

Model guided trait-specific co-expression network estimation as a new perspective for identifying molecular interactions and pathways

A network toxicology approach for mechanistic modelling of nanomaterial hazard and adverse outcomes